ZYUS Life Sciences launches a C$15–16 million LIFE offering to advance cannabinoid drug development and regulatory execution. Find out what it signals.
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.
Find out how zenocutuzumab could change treatment strategies in NRG1+ pancreatic cancer after progression. Explore new ASCO GI 2026 data today.
bit.bio raised $50M to expand its human cell programming platform for toxicology and AI model training. Find out why investors are backing NAMs now.
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
MindWalk says flu can’t mutate past this. Find out how its HYFT AI platform found a functional constraint that may redefine universal vaccine design.
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.
Camurus AB announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of the New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly. The agency assigned a Prescription Drug User Fee Act (PDUFA) action date of June 10, 2026, reinitiating regulatory review after an earlier Complete Response Letter related